Stromal Cells for GVHD Prevention
Interferon γ-Primed Mesenchymal Stromal Cells as Prophylaxis for Acute Graft v Host Disease After Allogeneic Hematopoietic Cell Transplantation for Patients With Hematologic Malignancies and Myelodysplasia
More Information
- Trial Status
- Not currently accepting
- Trial Phase
- Phase 1
- Enrollment
- 45 patients (estimated)
- Sponsors
- Ossium Health, Inc.
- Collaborators
- Winship Cancer Institute
- Tags
- Post-Allogeneic Stem Cell Transplant
- Trial Type
- Supportive
- Last Update
- 2 months ago
- SparkCures ID
- 1547
- NCT Identifier
- NCT04328714
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.